Author:
Reams Jennifer,Berger Andrea,Denio Alfred
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference16 articles.
1. 2015 American college of rheumatology guidelines for the treatment of rheumatoid arthritis;Singh;Arthritis Care Res,2016
2. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial;Smolen;Lancet,2009
3. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase;Schiff;Ann Rheum Dis,2014
4. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug;Gottenberg;JAMA,2016
5. Treatment persistence and healthcare costs among patients with rheumatoid arthritis after a change in targeted therapy;Bonafede;Am Health Drug Benefits,2018
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献